Tuesday, 16 February 2016

Tysabri and the risk of PML

Many readers of this blog are quite aware of the benefits & risks involved in the treatment of MS with Tysabri; now the EMA has officially reviewed the PML risk. BartsMS, and I'm sure a number of other centres, have for quite some time adopted the use of antibody titre and high frequency screening/MRI scanning as part of their management of pwRMS on natalizumab.  If you are on Tysabri this tool will give you and estimate of your personal risk.

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.